Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  American Journal of Cardiology

• Publication date

  1998-08-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0002-9149(98)00488-3PMID 9719019
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

  1996cited by this paper
• Sample size calculation for complex clinical trials with survival endpoints.

  1995cited by this paper
• A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.

  1995cited by this paper
• Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.

  1993cited by this paper
• Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure

  1993cited by this paper
• Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions.

  1992cited by this paper
• Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

  1992cited by this paper
• Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

  1991cited by this paper
• Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

  1988cited by this paper
• Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

  1987cited by this paper
• Analysis of Survival Data

  1984cited by this paper
• Discrete sequential boundaries for clinical trials

  1983cited by this paper
• A multiple testing procedure for clinical trials.

  1979cited by this paper
• Allocation of patients to treatment groups in a controlled clinical study.

  1978cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.

  2023cites this paper
• Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study

  2022cites this paper
• Klotho, fibroblast growth factor‐23, and the renin–angiotensin system — an analysis from the PEACE trial

  2019cites this paper
• Traditional Risk Factors Versus Biomarkers for Prediction of Secondary Events in Patients With Stable Coronary Heart Disease: From the Heart and Soul Study

  2015cites this paper
• Computational modelling of atherosclerosis

  2015cites this paper
• Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease.

  2014cites this paper
• Ramipril

  2012cites this paper
• Outcomes and Risk Prediction Model for Peripheral Arterial Disease in Patients with Stable Coronary Artery Disease

  2011cites this paper
• Antihypertensive Treatment and Secondary Prevention of Cardiovascular Disease Events Among Persons Without Hypertension

  2011cites this paper
• Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis.

  2011cites this paper
• Opposing effects of β blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease.

  2011cites this paper
• Preserved or slightly depressed ejection fraction and outcomes after myocardial infarction

  2011cites this paper
• A Pharmacological mechanism for the Clinical Benefits of Angiotensin Converting Enzyme Inhibitors: Analyses of randomised controlled trials

  2010cites this paper
• Evaluating equivalence and noninferiority trials.

  2010cites this paper
• ACE inhibitors or sartans in the management of myocardial infarction survivors

  2009cites this paper
• Inhibitory ACE nebo sartany v léčbě pacientů po infarktumyokardu

  2009influential citation
• Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors or Angiotensin IIReceptor Blockers for Ischemic Heart Disease

  2009cites this paper
• Angiotensin inhibition in renovascular disease: a population-based cohort study.

  2008cites this paper
• АНГИОТЕНЗИН II И ИНФАРКТ МИОКАРДА

  2008cites this paper
• Tolerability of Sibutramine During a 6-week Treatment Period in High-Risk Patients With Cardiovascular Disease and/or Diabetes: A Preliminary Analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial

  2008cites this paper
• Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease

  2007cites this paper
• Long-Term Trandolapril Treatment Is Associated With Reduced Aortic Stiffness: The Prevention of Events With Angiotensin-Converting Enzyme Inhibition Hemodynamic Substudy

  2007cites this paper
• ROLE OF MECHANICAL VERSUS HUMORAL EFFECTS OF ANGIOTENSIN II ON VASCULAR REMODELING

  2006cites this paper
• Renal Dysfunction, Cardiovascular Risk, and the Response to Ace Inhibition in Patients After Myocardial Infarction

  2006cites this paper
• Obesity and cardiovascular events in patients with established coronary disease.

  2006cites this paper
• Heart failure: from bench to bedside

  2006cites this paper
• Chicken's valve in a human heart.

  2006cites this paper
• Renal Function and Effectiveness of Angiotensin-Converting Enzyme Inhibitor Therapy in Patients With Chronic Stable Coronary Disease in the Prevention of Events with ACE inhibition (PEACE) Trial

  2006cites this paper
• ROLE OF MECHANICAL VERSUS HUMORAL EFFECTS OF ANGIOTENSIN II ON VASCULAR REMODELING

  2006influential citation
• Angiotensin-converting enzyme inhibition in patients with coronary artery disease and preserved left ventricular function Ischemia Management with Accupril post-bypass graft via inhibition of angiotensin-converting enzyme (IMAGINE) compared with the other major trials in coronary artery disease.

  2006cites this paper
• Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials

  2006cites this paper
• Inhibitory ACE v sekundární prevenci ICHS - Studie PEACE

  2006cites this paper
• Opening the Adaptive Toolbox

  2006cites this paper
• Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function?

  2006cites this paper
• Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.

  2006cites this paper
• No PEACE for ACE Inhibitors

  2005cites this paper
• New Considerations Relating to Class Effect With Angiotensin‐Converting Enzyme Inhibitors‐The PEACE Study

  2005cites this paper
• Provision of cardiovascular protection by ACE inhibitors:a review of recent trials

  2004cites this paper
• Angiotensin-converting-enzyme inhibition in stable coronary artery disease.

  2004cites this paper
• Preserving bradykinin or blocking angiotensin II: the cardiovascular dilemma

  2004cites this paper
• Inhibitors of the RAS: Evidence-Based Medicine

  2004cites this paper
• Drugs Blocking the Renin-Angiotensin-Aldosterone System

  2004cites this paper
• PERTINENT—PERindopril–Thrombosis, InflammatioN, Endothelial Dysfunction and Neurohormonal Activation Trial: A Sub-Study of the EUROPA Study

  2004cites this paper
• Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEM

  2003cites this paper
• Trandolapril: a newer angiotensin-converting enzyme inhibitor.

  2003cites this paper
• [Vascular wall renin-angiotensin system as a target of therapeutic interventions].

  2003cites this paper
• Can Angiotensin-converting Enzyme Inhibitors Reverse Atherosclerosis?

  2003cites this paper
• Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial.

  2003cites this paper
• Angiotensin-converting enzyme (ACE) inhibitor therapy after myocardial infarction in relation to left ventricular function

  2003cites this paper
• Angiotensin Converting Enzyme Inhibitors After and During Acute Coronary Syndromes, and, in Particular, Myocardial Infarction

  2003cites this paper
• Inhibitory konwertazy angiotensyny w leczeniu choroby niedokrwiennej serca - w oczekiwaniu na EUROPĘ

  2003cites this paper
• New Therapeutic Options in Congestive Heart Failure: Part II

  2002cites this paper
• Current indications for ACE inhibitors and HOPE for the future.

  2002cites this paper
• Ongoing trials involving angiotensin-converting enzyme inhibitors

  2002cites this paper
• McMurray and Pfeffer New Therapeutic Options in CHF : Part I 2101

  2002cites this paper
• New therapeutic options in congestive heart failure: Part I.

  2002cites this paper
• Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease.

  2002cites this paper
• Review: Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension

  2002cites this paper
• The prevalence of treatable left ventricular systolic dysfunction in patients who present with noncardiac vascular episodes: a case-control study.

  2002cites this paper
• The Angiotensin-receptor Blockers: From Antihypertensives to Cardiovascular All-round Medications in 10 Years?

  2002cites this paper
• Ischemia Management with Accupril post bypass Graft via Inhibition of angiotensin coNverting enzyme (IMAGINE): a multicentre randomized trial - design and rationale.

  2002cites this paper
• Vascular and cardiac benefits of angiotensin receptor blockers.

  2002cites this paper
• Antihipertensivos clásicos o modernos en el tratamiento de la hipertensión arterial: ¿debe seguir existiendo controversia en su elección?

  2002cites this paper
• ACE inhibitors and diabetes: from HOPE to PROGRESS

  2002cites this paper
• Ramiprilof its Use in the Prevention of Cardiovascular Outcomes

  2002cites this paper
• Resolution of renal artery thrombus with direct administration of tissue plasminogen activator

  2002cites this paper
• New Therapeutic Options in Congestive Heart Failure: Part I Clinical Cardiology: New Frontiers

  2002cites this paper
• Beyond Remodeling: A New Paradigm for Angiotensin‐Converting Enzyme Inhibitors Following Myocardial Infarction

  2001cites this paper
• The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data.

  2001cites this paper
• Role of bradykinin and eNOS in the anti‐ischaemic effect of trandolapril

  2001cites this paper
• A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients.

  2001cites this paper
• The Denolin lecture. Congestive heart failure: a half century perspective.

  2001cites this paper
• WHAT IS THE RELEVANCE OF THE HOPE STUDY IN GENERAL PRACTICE?

  2001cites this paper
• Diagnosis and management of myocardial ischemia (angina) in the elderly patient.

  2001cites this paper
• Contemporary Management of Chronic Stable Angina

  2001cites this paper
• The EUROPA Trial: Design, Baseline Demography and Status of the Substudies

  2001cites this paper
• Issues in discharge therapy after hospitalization for UA/NSTEMI

  2001cites this paper
• The continuation of the Prevention of Events With Angiotensin-Converting Enzyme Inhibition (PEACE) Trial.

  2001cites this paper
• The general concepts of an equivalence trial, applied to ASSENT-2, a large-scale mortality study comparing two fibrinolytic agents in acute myocardial infarction.

  2001cites this paper
• Ongoing trials of angiotensin-converting enzyme inhibition: what they can tell us.

  2001cites this paper
• Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis.

  2001cites this paper
• Evaluative and epidemiological approaches of ACE therapy

  2001cites this paper
• Secondary prevention: improving outcomes following myocardial infarction

  2000cites this paper
• Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders.

  1998cites this paper